Astria Therapeutics, Inc. (ATXS)
Jan 26, 2026 - ATXS was delisted (reason: acquired by BCRX)
12.58
0.00 (0.00%)
Inactive · Last trade price on Jan 22, 2026
Astria Therapeutics Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Astria Therapeutics stock had an average target of $24.33, with a low estimate of $13 and a high estimate of $47.
Price Target: $24.33 (+93.40%)
Analyst Consensus: Hold
Price Target
Analyst Ratings
The average analyst rating for Astria Therapeutics stock from 6 stock analysts was "Hold". This means that analysts believed this stock was likely to perform similarly to the overall market.
Recommendation Trends
No data available
| Rating | Oct 2026 |
|---|---|
| Strong Buy | n/a |
| Buy | n/a |
| Hold | n/a |
| Sell | n/a |
| Strong Sell | n/a |
| Total | n/a |
Financial Forecast
Revenue This Year
8.74M
Revenue Next Year
3.57M
from 8.74M
Decreased by -59.15%
EPS This Year
-2.20
from -1.68
EPS Next Year
-2.27
from -2.20
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 16.8M | 8.4M | ||||
| Avg | 8.7M | 3.6M | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | -3.9% | ||||
| Avg | - | -59.2% | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -1.94 | -1.73 | ||||
| Avg | -2.20 | -2.27 | ||||
| Low | -2.48 | -2.69 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |